Phase I Study of Selinexor with Nivolumab and Ipilimumab in Asian Solid Tumours
A Phase I clinical trial, led by N2CR clinician-scientist A/Prof David Tan, tested a new drug combination—Selinexor, nivolumab (NIVO), and ipilimumab (IPI)—in Asian patients with advanced solid tumours/cancers and had […]